Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection
Katarina Tomović, Jelena Lazarević, Gordana Kocić, et al.
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 404-422
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 294
COVID‐19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Margaret F. Bassendine, Simon H. Bridge, Geoffrey W. McCaughan, et al.
Journal of Diabetes (2020) Vol. 12, Iss. 9, pp. 649-658
Open Access | Times Cited: 145
Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
Michał Konwerski, Aleksandra Gąsecka, Grzegorz Opolski, et al.
Biology (2022) Vol. 11, Iss. 3, pp. 355-355
Open Access | Times Cited: 72
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Kunika Saini, Smriti Sharma, Yousuf Aziz Khan
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 66
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
Nami Lee, Yu Jung Heo, Sung‐E Choi, et al.
Journal of Immunology Research (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 101
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study
Richeek Pradhan, Sally Lu, Hui Yin, et al.
BMJ (2022), pp. e071380-e071380
Open Access | Times Cited: 60
Epicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation
Maddalena Conte, Laura Petraglia, Serena Cabaro, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 53
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 37
COVID-19: Diabetes Perspective—Pathophysiology and Management
Siva Dallavalasa, SubbaRao V. Tulimilli, Prakash Janhavi, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 184-184
Open Access | Times Cited: 24
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeong-Woo Lee, Hyewon Nam, et al.
Diabetes & Metabolism Journal (2021) Vol. 45, Iss. 2, pp. 251-259
Open Access | Times Cited: 54
Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Current Molecular Pharmacology (2021) Vol. 15, Iss. 4, pp. 683-692
Closed Access | Times Cited: 45
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Petr Bušek, Jonathan S. Duke‐Cohan, Aleksi Šedo
Cancers (2022) Vol. 14, Iss. 9, pp. 2072-2072
Open Access | Times Cited: 29
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
André Scheen
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101213-101213
Open Access | Times Cited: 43
Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
Ahmed Elsanhoury, Vivian Nelki, Sebastian Kelle, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 40
Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
Badrud Duza Mohammad, Mirza Shahed Baig, Neeraj Bhandari, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6001-6001
Open Access | Times Cited: 20
The importance of microvascular inflammation in ageing and age-related diseases: a position paper from the ESH working group on small arteries, section of microvascular inflammation
Alessandro Mengozzi, Carolina De Ciuceis, Raffaella Dell’Oro, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 10, pp. 1521-1543
Open Access | Times Cited: 12
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions
Alfredo Caturano, Erica Vetrano, Raffaele Galiero, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10173-10173
Open Access | Times Cited: 4
VILDAGLIPTIN IMPROVES DETRUSOR CONTRACTILITY IN A MOUSE MODEL OF CYCLOPHOSPHAMIDE-INDUCED OVERACTIVE BLADDER
Seçkin Engin, Elif Nur Barut, M Karaca, et al.
Ankara Universitesi Eczacilik Fakultesi Dergisi (2025) Vol. 49, Iss. 1, pp. 5-5
Open Access
Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies
Fang Yu, Jia Chen, Xiaoyue Wang, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology
Melania Gaggini, Laura Sabatino, Adrian Florentin Suman, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 387-387
Open Access
SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus
Hasan Fehmi Özel, Şüheda Alpay, Emre Asker, et al.
Journal of Diabetes and its Complications (2025), pp. 109021-109021
Closed Access
DPP-IV and FAS inhibitory peptides: therapeutic alternative against diabesity
Ma. Fabiola León‐Galván, Daniela Sarahi Medina-Rojas
Journal of Diabetes & Metabolic Disorders (2025) Vol. 24, Iss. 1
Closed Access
Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 31
Inhibiting DPP4 activity protects hiPSC-derived steatotic HLCs by supporting fatty acid and purine metabolism and dampening inflammation
Christiane Lörch, Wasco Wruck, R. J. Julian, et al.
Research Square (Research Square) (2025)
Open Access
Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective
Faraha Ahmed, Syed Sufian Ahmad, Mohammad Mumtaz Alam, et al.
Beni-Suef University Journal of Basic and Applied Sciences (2025) Vol. 14, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top